Prolonged remission of HIV-associated multicentric Castelman's disease with an anti-CD20 monoclonal antibody as primary therapy.
Prolonged remission of HIV-associated multicentric Castelman's disease with an anti-CD20 monoclonal antibody as primary therapy.
复制标题
使用抗 CD20 单克隆抗体作为主要治疗可延长 HIV 相关多中心 Castelman 病的缓解。
DOI：
10.1097/00002030-200306130-00023
复制
发表时间：
2003
期刊：
影响因子：
3.8
通讯作者：
O. Lortholary
中科院分区：
文献类型：
--
作者：
F. Marrache;C. Larroche;N. Mémain;O. Bouchaud;M. Robineau;O. Hermine;O. Lortholary
多中心Castleman病是一种非典型淋巴组织增生性疾病，其特征为淋巴结病伴血管滤泡增生和浆细胞浸润[1]。在过去的十年中，已报告HIV感染患者与人类疱疹病毒8（HHV-8）感染相关[2，3]。这类患者的治疗主要以长春碱等化疗为主，预后较差[2]。最近，有报道称，抗CD 20单克隆抗体治疗联合高效抗逆转录病毒治疗（HAART）可使多中心Castelman病缓解14个月，尽管患者在接受西多福韦和抗人IL-6单克隆抗体治疗后复发，化疗可部分维持缓解[4]。
Multicentric Castleman’s disease is an atypical lymphoproliferative disorder characterized by lymphadenopathy with angiofollicular hyperplasia and plasma cell infiltration [1]. During the past decade, it has been reported in HIV-infected patients in association with human herpesvirus 8 (HHV-8) infection [2,3]. In this group of patients, treatment is mainly based on antineoplastic chemotherapy such as vinblastine, and prognosis is poor [2]. Recently, a case of a 14-month remission of multicentric Castelman’s disease has been reported with anti-CD20 monoclonal antibody therapy in association with highly active antiretroviral therapy (HAART), although remission was partly maintained with chemotherapy after the patient had relapsed when receiving cidofovir and antihuman IL-6 monoclonal antibody [4].
移植后淋巴细胞增殖性疾病患者中 Epstein-Barr 病毒感染的 B 细胞的特征：利妥昔单抗治疗后消失并不能预测临床反应。
影响因子：
20.3
作者：
Yang,J;Tao,Q;Flinn,IW;Murray,PG;Post,LE;Ma,H;Piantadosi,S;Caligiuri,MA;Ambinder,RF
通讯作者：
Ambinder,RF